32
total announcements
THYROCARE.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 20 Oct 2026
Market Cap
₹7,497 Cr
P/E (TTM)
42.7
P/E (Forward)
29.6
EPS (TTM)
₹11.02
52W Low
₹342.55
52W High
₹662.00
Dividend Yield
1.92%
Beta
0.45
Price / Book
12.8
Debt / Equity
8.7
Revenue (TTM)
₹876 Cr
Gross Margin
54.96%
Operating Margin
26.99%
Thyrocare Technologies Limited
Thyrocare Technologies Limited has submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming that the company's shares are in demat form and no requests for rematerialization were received during the quarter ended September 30, 2026.
Thyrocare Technologies Limited
Thyrocare Technologies Limited has informed the Exchange about Copy of Newspaper Publication for Notice of Postal Ballot. The company has published a notice in newspapers regarding the reduction of share capital of MackSoftTech Private Limited.
Thyrocare Technologies Limited
Thyrocare Technologies Limited has informed the Exchange regarding Notice of Postal Ballot for seeking approval of the Members of the Company by way of Postal Ballot through remote e-voting, in respect of the resolutions as set out in this Postal Ballot Notice.
Thyrocare Technologies Limited
Thyrocare Technologies Limited has informed the Exchange about Grant of Options under Thyrocare Employee Stock Option Scheme, where 1,92,000 options were granted to eligible employees at an exercise price of Rs. 10/- per Option.
Thyrocare Technologies Limited
Thyrocare Technologies Limited has informed the Exchange regarding the closure of the trading window for designated persons and their immediate relatives due to the declaration of un-audited financial results for the quarter and half year ended September 30, 2026.
Thyrocare Technologies Limited
Thyrocare Technologies Limited has informed about the sale of its entire shareholding in Nueclear Healthcare Limited, a material wholly owned subsidiary, to Trovera Healthcare Private Limited. The sale consideration is approximately Rs. 1,41,40,00,000/-, comprising 42,500 Compulsorily Convertible Preference Shares and a cash component of Rs. 81,90,00,000/-.
Thyrocare Technologies Limited
Thyrocare Technologies Limited has announced the sale of its entire shareholding in Nueclear Healthcare Limited, a material wholly owned subsidiary, to Trovera Healthcare Private Limited for approximately Rs. 1,41,40,00,000. As part of the consideration, the company will acquire 42,500 Compulsorily Convertible Preference Shares of Trovera.
Thyrocare Technologies Limited
Thyrocare Technologies Limited has informed the Exchange regarding the outcome of the Board Meeting held on September 21, 2026, where the Board approved the sale of its entire shareholding in Nueclear Healthcare Limited to Trovera Healthcare Private Limited for approximately Rs. 1,41,40,00,000/-, and the acquisition of Compulsorily Convertible Preference Shares of Trovera as part-consideration for the sale.
Thyrocare Technologies Limited
API Holdings Limited has submitted a disclosure under SEBI Takeover Regulations regarding the amalgamation of Docon Technologies Private Limited with API Holdings Limited, resulting in API acquiring 51.02% of Thyrocare Technologies Limited's paid-up share capital.
Thyrocare Technologies Limited
Thyrocare Technologies Limited has informed the Exchange about Copy of Newspaper Publication pertaining to Notice of transfer of equity shares of the Company to Investor Education and Protection Fund.
Thyrocare Technologies Limited
Thyrocare Technologies Limited has informed the Exchange regarding the approval of the Scheme of Amalgamation of Docon Technologies Private Limited with API Holdings Limited by the Hon'ble National Company Law Tribunal, Mumbai Bench.
Thyrocare Technologies Limited
Thyrocare Technologies Limited has informed the Exchange regarding the complete discharge and release of Transaction Documents pursuant to full redemption and repayment of Non-Convertible Debentures by API Holdings Limited.
Thyrocare Technologies Limited
Thyrocare Technologies Limited has submitted a disclosure under SEBI Takeover Regulations, as per Regulation 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
Thyrocare Technologies Limited
Thyrocare Technologies Limited has received a disclosure from Docon Technologies Private Ltd under SEBI Takeover Regulations, submitting a copy of Disclosure under Regulation 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
Thyrocare Technologies Limited
Thyrocare Technologies Limited has received a communication from its promoter, Docon Technologies Private Limited, regarding the release of a pledge on 7,94,69,696 equity shares of the company. The pledge was created to secure the obligations of API Holdings Limited, the holding company, in respect of non-convertible debentures. The debentures have been fully redeemed and repaid, and the pledge has been fully released.
Thyrocare Technologies Limited
Thyrocare Technologies Limited has informed the Exchange regarding communication received from Promoter regarding sale of 1,57,69,696 Equity Shares of the Company by Promoter - Docon Technologies Private Limited. The shares sold represent approximately 9.90% of the total paid-up equity share capital of the Company. Following the aforesaid transaction, Docon continues to be a Promoter and holding company of Thyrocare.
Thyrocare Technologies Limited
Thyrocare Technologies Limited has received a communication from its promoter, Docon Technologies Private Limited, regarding the release of a pledge on 1,75,00,000 equity shares held by Docon. The shares were pledged as security for non-convertible debentures issued by API Holdings Limited, the holding company of Docon. The release of the pledge was done by Catalyst Trusteeship Limited, acting as the debenture trustee, on August 11, 2026.
Thyrocare Technologies Limited
Thyrocare Technologies Limited has informed the Exchange about Earnings Call Transcript held on July 23, 2026. The transcript is available on the company's website and will be uploaded on the Stock Exchange website. The discussion may be forward looking in nature and must be viewed in relation to the risks pertaining to the business.
Thyrocare Technologies Limited
Thyrocare Technologies Limited has resubmitted its unaudited financial results for the quarter ended June 30, 2026, in machine-readable format, as per the National Stock Exchange's circular.
Thyrocare Technologies Limited
Thyrocare Technologies Limited has published unaudited financial results for the quarter ended June 30, 2026, in newspapers and on its website.